Trials / Not Yet Recruiting
Not Yet RecruitingNCT07365462
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Neurocrine Biosciences · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NBI-1065890 | Oral administration |
| DRUG | Placebo | Oral administration |
Timeline
- Start date
- 2026-01-01
- Primary completion
- 2027-02-01
- Completion
- 2027-03-01
- First posted
- 2026-01-26
- Last updated
- 2026-01-26
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07365462. Inclusion in this directory is not an endorsement.